Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
$0.19
+5.6%
$0.16
$0.12
$4.55
$1.58M-0.141.25 million shs49,770 shs
Fresh Tracks Therapeutics, Inc. stock logo
FRTX
Fresh Tracks Therapeutics
$0.94
-0.5%
$0.94
$0.03
$1.03
$5.59M0.542,709 shs2,402 shs
GT Biopharma, Inc. stock logo
GTBP
GT Biopharma
$2.89
$2.35
$1.72
$4.10
$7.47M1.48245,521 shs100,114 shs
NLS Pharmaceutics Ltd. stock logo
NLSP
NLS Pharmaceutics
$2.08
+12.4%
$1.55
$1.30
$18.39
$7.48M-0.21869,928 shs381,139 shs
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
+5.56%+0.16%+31.03%+6.15%-90.64%
Fresh Tracks Therapeutics, Inc. stock logo
FRTX
Fresh Tracks Therapeutics
0.00%0.00%0.00%+0.54%+3.87%
GT Biopharma, Inc. stock logo
GTBP
GT Biopharma
0.00%+33.80%+26.75%+22.46%-21.47%
NLS Pharmaceutics Ltd. stock logo
NLSP
NLS Pharmaceutics
+12.43%+20.23%+38.67%+15.88%+1,095.40%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
2.0257 of 5 stars
3.50.00.00.02.60.01.3
Fresh Tracks Therapeutics, Inc. stock logo
FRTX
Fresh Tracks Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
GT Biopharma, Inc. stock logo
GTBP
GT Biopharma
3.4993 of 5 stars
3.85.00.00.03.30.81.3
NLS Pharmaceutics Ltd. stock logo
NLSP
NLS Pharmaceutics
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
3.00
Buy$20.0010,426.32% Upside
Fresh Tracks Therapeutics, Inc. stock logo
FRTX
Fresh Tracks Therapeutics
0.00
N/AN/AN/A
GT Biopharma, Inc. stock logo
GTBP
GT Biopharma
3.50
Strong Buy$11.00280.62% Upside
NLS Pharmaceutics Ltd. stock logo
NLSP
NLS Pharmaceutics
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
N/AN/AN/AN/A$0.71 per shareN/A
Fresh Tracks Therapeutics, Inc. stock logo
FRTX
Fresh Tracks Therapeutics
$10.06M0.56N/AN/A$1.66 per share0.56
GT Biopharma, Inc. stock logo
GTBP
GT Biopharma
N/AN/AN/AN/A$5.42 per shareN/A
NLS Pharmaceutics Ltd. stock logo
NLSP
NLS Pharmaceutics
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
-$16.08MN/A0.00N/AN/AN/A-2,842.40%-337.48%N/A
Fresh Tracks Therapeutics, Inc. stock logo
FRTX
Fresh Tracks Therapeutics
-$5.69M-$1.41N/AN/AN/AN/AN/AN/A
GT Biopharma, Inc. stock logo
GTBP
GT Biopharma
-$7.60M-$5.69N/AN/AN/AN/A-257.47%-131.09%8/13/2025 (Estimated)
NLS Pharmaceutics Ltd. stock logo
NLSP
NLS Pharmaceutics
-$12.17MN/A0.00N/AN/AN/AN/AN/A

Latest BPTH, FRTX, NLSP, and GTBP Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
GT Biopharma, Inc. stock logo
GTBP
GT Biopharma
-$0.64-$0.76-$0.12-$0.33N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
N/AN/AN/AN/AN/A
Fresh Tracks Therapeutics, Inc. stock logo
FRTX
Fresh Tracks Therapeutics
N/AN/AN/AN/AN/A
GT Biopharma, Inc. stock logo
GTBP
GT Biopharma
N/AN/AN/AN/AN/A
NLS Pharmaceutics Ltd. stock logo
NLSP
NLS Pharmaceutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
N/A
0.86
0.86
Fresh Tracks Therapeutics, Inc. stock logo
FRTX
Fresh Tracks Therapeutics
N/AN/AN/A
GT Biopharma, Inc. stock logo
GTBP
GT Biopharma
N/A
1.45
1.45
NLS Pharmaceutics Ltd. stock logo
NLSP
NLS Pharmaceutics
N/A
0.15
N/A

Institutional Ownership

CompanyInstitutional Ownership
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
5.74%
Fresh Tracks Therapeutics, Inc. stock logo
FRTX
Fresh Tracks Therapeutics
25.04%
GT Biopharma, Inc. stock logo
GTBP
GT Biopharma
8.15%
NLS Pharmaceutics Ltd. stock logo
NLSP
NLS Pharmaceutics
N/A

Insider Ownership

CompanyInsider Ownership
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
0.72%
Fresh Tracks Therapeutics, Inc. stock logo
FRTX
Fresh Tracks Therapeutics
0.23%
GT Biopharma, Inc. stock logo
GTBP
GT Biopharma
10.90%
NLS Pharmaceutics Ltd. stock logo
NLSP
NLS Pharmaceutics
16.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
108.31 million5.73 millionOptionable
Fresh Tracks Therapeutics, Inc. stock logo
FRTX
Fresh Tracks Therapeutics
205.97 million5.96 millionNot Optionable
GT Biopharma, Inc. stock logo
GTBP
GT Biopharma
82.59 million1.99 millionNo Data
NLS Pharmaceutics Ltd. stock logo
NLSP
NLS Pharmaceutics
63.60 million3.01 millionNot Optionable

Recent News About These Companies

NLS Pharmaceutics, Kadimastem announce up to $3M equity financing
NLS Pharmaceutics announces new preclinical data for AEX-2
NLS Pharmaceutics files $75M mixed securities shelf
NLS Pharmaceutics files to sell 645,161 common shares for holders
NLS Pharmaceutics’ merger approved by Kadimastem shareholders
NLS Gains on Deal with Kardimastem

New MarketBeat Followers Over Time

Media Sentiment Over Time

Bio-Path stock logo

Bio-Path NASDAQ:BPTH

$0.19 +0.01 (+5.56%)
As of 05/27/2025 12:47 PM Eastern

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing BP1001-A that is in Phase I clinical trial for the treatment of solid tumors; Liposomal Bcl-2 (BP1002), which is in Phase I clinical trial for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; and Liposomal STAT3 (BP1003) for treating pancreatic cancer, non-small cell lung cancer, and AML. The company was founded in 2007 and is based in Bellaire, Texas.

Fresh Tracks Therapeutics stock logo

Fresh Tracks Therapeutics NASDAQ:FRTX

$0.94 -0.01 (-0.53%)
As of 02/28/2025

Fresh Tracks Therapeutics, Inc. does not have significant operations. Previously, the company was engaged in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. Fresh Tracks Therapeutics, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.

GT Biopharma stock logo

GT Biopharma NASDAQ:GTBP

$2.89 0.00 (0.00%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$2.76 -0.14 (-4.67%)
As of 05/27/2025 07:19 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 (GTB-3550) TriKE fusion protein for cancer therapies; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California.

NLS Pharmaceutics stock logo

NLS Pharmaceutics NASDAQ:NLSP

$2.08 +0.23 (+12.43%)
Closing price 05/27/2025 03:59 PM Eastern
Extended Trading
$2.30 +0.22 (+10.34%)
As of 05/27/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company also developing NLS-4, a selective dopamine reuptake inhibitor to prevent rare sleep disorders; NLS-3, a repurposed reverse ester of methylphenidate for treatment of ADHD; NLS-8, a melatonin ML1A receptor agonist, improved scopolamine-induced amnesia; NLS-11, a norepinephrine and dopamine reuptake inhibitor and muscarinic M1, M2, M3 receptor antagonist; and NLS-12, a norepinephrine and dopamine reuptake inhibitor and muscarinic M4 receptor antagonist. NLS Pharmaceutics AG was incorporated in 2015 and is based in Zurich, Switzerland.